Candel Therapeutics, Inc Investor Event Transcript, Nov 18, 2026
Candel Therapeutics, Inc. (CADL)
Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028. AI summary
Conference Transcript - CADL 2026-11-18
Maury Raycroft, Analyst — Jefferies
Good morning, everyone. My name is Maury Raycroft and one of the biotech analysts at Jeffrey's. I'd like to welcome Paul Peter Tak, the CEO of Kandel Therapeutics. Thanks so much for joining us today, Paul Peter. Yeah, it's a great pleasure. And we're going to do fireside chat format, so maybe for those who are newer to the story, could you start with a brief introduction to Kandel and the two clinical stage programs, Agilid Imogene and Alena Serpiteru, and what is the common scientific idea underlying the portfolio?
Paul Peter Tak, Board Member
Yeah, Candel Therapeutics develops viral immunotherapies. We have two investigational medicines in the clinic. The first is called Aglatimogene-Besodenovec. We'll call it Aglatimogene for short. And it's a whole new way to turn basically the patient's own tumor. ...into a vaccine. So this is not a vaccine, but it leads ultimately to in-situ immunization or in-situ vaccination against the injected tumor and also against distant, uninjected metastases in metastatic disease. We've shown positive data based on a large, pivotal, placebo-controlled Phase III clinical trial in newly diagnosed, localized prostate cancer, area of huge unmet need, very big commercial opportunity. We have a special protocol assessment agreed with the FDA. We have a fast-track designation with the data in hand. We went to the new FDA and got RMAT designation as well, so we are preparing BLA submission. Second, we have very encouraging data based on a Phase II A clinical trial, open label, in a therapy-resistant condition, patients with progressive metastatic disease Who have failed immune checkpoint inhibitors in most cases, also chemotherapy. These patients have a very poor prognosis, typically a median overall survival of less than a year. We've shown doubling of expected median overall survival. We may come back to it. We just published these data supported by deep immunological biomarker data in the Journal of Immunotherapy of Cancer. And then we also have very nice data based on a small randomized controlled trial in so-called borderline resectable pancreatic cancer. We are going to publish this data in a few weeks. We've not announced this yet, but you can read that we have a complete separation of the overall survival curves, again supported by strong biomarker data. We got fast-track designation there, orphan drug designation as well. By the way, also fast-track designation in lung cancer. So that's aglatimogen. We may discuss it in more detail. That's the lead asset, and the lead indication is prostate cancer. And then the second investigation on medicine works in a slightly different way. It's also a viral immunotherapy. It's called glenoserepatorev. It's a replication-competent next-generation herpes simplex virus that has been designed to attack specifically the cancer cells that express nesting. So think of glioblastoma. We tested it in recurrent glioblastoma. We have also very encouraging data published in Nature, Science Translational Medicine, CELL, so it's top science, and we've shown doubling of expected median overall survival, and we're starting to see a small subset of patients that live much longer than you would expect, and we just announced these data. So, two investigational medicines in the clinic, and the overarching concept is we basically use viral and engineered viruses to ultimately immunize the patient against the patient's own tumor.
Maury Raycroft, Analyst — Jefferies
Got it. Yeah, I think that's a great intro, and you had some data at CITSI recently where you had new findings from your PRTK05 phase 2 study on localized prostate cancer. What do the studies show, and why are these data important beyond simply satisfying a BLA requirement?
Paul Peter Tak, Board Member
Yeah, so the FDA asked us to do a new biodistribution and shedding study. So basically, you look in different body compartments. For how long can you actually detect the viral gene construct? And we have data from the past, from the legacy company, showing that it's all gone within a few months. That is actually what you expect, because aglatimogene is a replication-defective adenovirus, so it should be gone over time. But also the cells that are infected, the cells that are transduced, are actually killed by using the prod work, which is valacytophir. But the FDA asked, and rightly so, I think, to repeat that experiment with state-of-the-art methods, and we've done that. So we presented on the poster at CITC, Late Breaking Abstract, on the bottom right, I've posted the poster so everybody can see it, that indeed what we've seen so far based on 17 patients is that the product is gone after several months. But the more interesting part for an immunologist is we took some extra samples from this trial, and also for this reason we added a control group to ask the question, If you inject aglatimogen in prostate cancer, into the prostate, which is a simple procedure that takes 15, 20 minutes, and you do it only three times in a patient's life, does it not only lead to an effect at the site of the injection, but does it also lead to a systemic immune response? And that's what we've shown. We've clearly shown the induction of proliferating CD8-positive, granzyme B-positive, that means there are cytotoxic T-cells in the circulation, and also the induction of memory effector cells and central memory cells. So why is that important? Because this is a systemic immunotherapy. That opens up other indications over time in prostate cancer. After approval, we will consider to go into oligometastatic disease, into more advanced disease, where you don't need to inject all the tumors. And we've shown exactly the same for aglatimogen in the past in, again, high-grade glioma, glioblastoma. We stopped that program because we cannot do everything at the same time, but we did have very encouraging data. We've shown there that a broadening of the T-cell receptor repertoire measured in the blood After a clotimogen injection into the brain, it's associated with improved survival. We published these data in Neuro-Oncology. We've shown the same in metastatic non-sponsored lung cancer, where you basically can inject one tumor, and where you see clinically an abscopal effect, that's evidence of a clinical systemic anti-tumor immune response, and we've seen something similar in pancreatic cancer. So I want to highlight this as an off-the-shelf therapy. That leads to an individualized anti-tumor immune response, specific for the patient's own tumor, and it's a palm-solid tumor approach that has worked in every solid tumor that we've tested.
Maury Raycroft, Analyst — Jefferies
Got it. Yeah, that's a great summary of the mechanism behind the drug. And how do the immune profiling, the biodistribution, and shedding findings from PRTK-05 strengthen the overall clinical and mechanistic package supporting EGLIN imaging in localized prostate cancer? And will the completed Phase II work be included in the original VLA, and is the immune analysis data set of 17 patients, is that sufficient to address the FDA's request?
Paul Peter Tak, Board Member
Yeah, so the request was really focused on the biodistribution and shedding data, and the FDA has agreed to accept these data, actually, if we filed the BLA. The study is still open because there's no minimum number of patients that you need for a biodistribution study. So we said, well, let's go up to 30 patients in the active treatment group because it allows us to do more immunological biomarker research. And therefore, we also added the control group of 15 patients. This was not requested by the FDA, but it will lead to a better publication. It's always good to have a control group. So we're still adding a few patients. I think we only need one more patient in each group, actually, and then we have the 45 patients already. So we have sufficient to submit to the FDA, but they did not ask for the biomarker data. The immunological biomarker data probably will add it as a supplementary appendix Because it really supports the consistent story across multiple solid tumors.
Maury Raycroft, Analyst — Jefferies
Got it. Okay. And recently you announced the delay with the BLA. Let's talk about the revised timelines there. You now expect to complete the submission in mid-27. When did you first become aware that the IUSA could affect the timeline, and what changed between successful qualification and formal validation?
Paul Peter Tak, Board Member
Yeah. We had the data readout in December 2024, And we've always said that we aim to have the whole package completed in two years, which is a very tight timeline. In every meeting, I've always been absolutely clear that every experiment needs to work to achieve that timeline. Actually, we've made tremendous progress, and we were on track until very recently. And then it came to my attention, actually, I know exactly when, November the 9th at 9.30, which was the meeting that I had with my CMC team. We have these regular updates about the relay submission, but it became clear that we will need six months for the validation of the so-called RU assay. So what does that mean? That's the infectivity unit assay. So what was on the critical path all this time? Manufacturing. You need to produce the commercial product. You need to show the consistency of it. You need to develop all the assays to show that it's comparable in terms of analytical comparability. That means you do it in the lab. It's not needed to do it in the clinic, right, in patients, and the FDA agreed to this. And then you need to have all these assays to also, after stability, it was also on the critical path, you put the product on stability, and then you apply all these assays to show that it's still the same product as at the beginning, before you put it in the freezer or in the fridge. One of these assays needed more time. We have successfully developed it, the IU assay. We have successfully qualified it. We've used it. But then to be able to use it in the commercial space, you also need to validate it. And the issue that we were dealing with is the variability. So there's a CV, which is the coefficient for variability, and we have complete agreement with the FDA about what they want to see, and the CV needs to be consistently lower than 30%. So, again, that's a measure of variability. You need to have very consistent results before you can use this for commercial release in the future. And we achieved that in several runs, but we did not achieve it in all the runs. That means that you need to start all over again, in a way, in terms of the validation process. And we've taken the following measures. And so we became aware of this on November the 9th. We've announced this three days later in the 10Q. One day later, on the last Friday, we've been pretty busy talking to all the analysts and many of our key investors to explain what we were dealing with and also how are we going to address this. This is not rocket science. It's just work that needs to happen. So what are we going to do? First, we are going to use more plates, in other words, more replicates. That means you bring up the N, which is, of course, a very obvious way to reduce the variability. So per essay, per test, we will have more replicates. That's one. Second, by comparing the runs that were successful compared to those where there was variability, We discovered that some people find it difficult to distinguish between the psychopathic effect of the virus, that's actually what you want to show, that's a measure of the infectivity unit assay, versus cells that spontaneously die in the in vitro cell-based experiment. Everybody who's done work in the lab in cell biology knows that cells, especially when they age, may die. There are morphological differences between the two. But you need to be able to distinguish between these two. So the second measure is that we found that if you have to read out on day 11 rather than on day 12, you have actually reduced variability. So moving forward, we will not only look at day 12. We'll still do that for comparability to the previous essays. But we will also have an essay readout on day 11 to minimize variability. The other point is aging, spontaneous aging leading to cell death in these assays is related to the number of passages. The more passages, the older the cells will be on average, the higher the chance that they will die spontaneously. So we're going to limit the number of passages in these assays. And then very importantly, we are going to give, and we've started to do this already in the pre-validation work that we've done, We are going to give additional training to the operators so that they all know what they need to look for in exactly the same way. So that takes six months. So we became aware of this. I became aware of this on November the 9th, so just a week ago, that it will take six months. So why does it take so long? Every essay will take about two weeks. Two days to set up the assay, and then, as I said, you need to read out on day 11, but also day 12, so that means two weeks per assay. You need to do about 20 to 25 replicates, and you cannot do all of that in parallel. So this is all ruled by the FDA, and we have complete alignment about what they want to see. We had that already from the beginning. I think that means you will need to do several of these essays sequentially, over time, done by different operators on different days. That gets us to a timeline of six months, which includes, actually, the possibility, if needed, to use the new or optimized IU essay for the comparability between the commercial batches. And the original batches that we used in the clinical trial. So this is included in the timeline. And we don't need additional manufacturing work. This should be absolutely clear. This has nothing to do with manufacturing. We've actually executed on the PPQ batches. This is purely an analytical essay topic. This is, again, not rocket science. We know exactly what to do. We've not discussed it with the FDA because we don't need to, because we know exactly what they want to see, and not all runs past the test of the CV of less than 30%.
Maury Raycroft, Analyst — Jefferies
Got it. Yeah, there's a lot of detailed information in there. I appreciate the transparency on what's going on. For the variability, any more perspective into where that's coming from? You mentioned the cell passages, like some of the issues. So is it mostly with the cell-based assay, or is there any operator-driven factors?
Paul Peter Tak, Board Member
Yeah, it's both. So if too many cells die based on the spontaneous effect related to aging, you will have more cell death unrelated to the psychopathic effect of the virus. And so that's one part, and we'll reduce that, as I laid out. But also, we will give additional training to the operators so that they get better, actually, at distinguishing between the psychopathic effect versus spontaneous aging. And we've started to do this work also in the pre-validation work, and we are very optimistic that we'll get there.
Maury Raycroft, Analyst — Jefferies
Got it. And you're also working on an aggregation assay. Why was that assay added, and where does its validation stand, and could it become another critical path?
Paul Peter Tak, Board Member
Yeah, this is actually a new request from the FDA in general, not only to us, but to everybody. There's new guidance about aggregation assays. This is not on the critical path.
Maury Raycroft, Analyst — Jefferies
Got it. Okay. And where do you stand on manufacturing more broadly? Are preliminary comparability results continuing to trend, as expected?
Paul Peter Tak, Board Member
Yeah, that's correct. So we have been successful in terms of manufacturing. We have delivered and executed the PPQ. So, of course, we need to test that with all the assays that we have developed, and then finally, potentially, again, with the optimized IU essay that I just described in more detail. We've started to do comparability studies because there are many assays that you use. And so far, all the data show that this trends in the right direction in terms of comparability between the new product and the old product.
Maury Raycroft, Analyst — Jefferies
And will the three drug substance and drug product PPQ batches already manufactured remain usable once the assays are validated, and can retained samples be retested, or is there any scenario in which new PPQ lots will be required?
Paul Peter Tak, Board Member
Yeah. The answer to all the two questions, the first two questions is yes. So we have this, and we can retest this. So we've stored all these samples, and we can use them. We don't need to manufacture a new product for the additional testing.
Maury Raycroft, Analyst — Jefferies
Got it, and, um... Has the IUSA, including the revised validation plan and acceptance criteria, been discussed with the FDA? And if so, what level of alignment do you have? And when you say the timeline is pending the result of that dialogue, what specific feedback could move the mid-2027 submission earlier or later?
Paul Peter Tak, Board Member
Yeah, so we have not discussed it with the FDA because there's really nothing to discuss. We have alignment with the FDA, as I've said, during previous fireside chats and panel discussions. We know exactly what they want to see. They've been very clear. We've had very constructive meetings about this, and they've been very clear about what is needed in terms of the CV, right, the measure of variability, and we've not achieved that in all the runs, so we just need to bring this down to less than 30 percent consistently, and then we will be able to submit this to the FDA.
Maury Raycroft, Analyst — Jefferies
Got it. And is mid-2027, is that the expected timing for the complete BLA submission? Or could you begin a rolling submission earlier by filing the clinical and non-clinical modules while Module 3 is being completed?
Paul Peter Tak, Board Member
Yeah, probably it's good to clarify that. Thank you for the question. So we've given the guidance in the past that we aimed to initiate the BLA submission at the end of this year, which is in December, basically, right? And now we give guidance about the completion of the BLA submission. We are in discussion, or we will be in discussion with the FDA about the optimal filing strategy, whether that's going to be a rolling BLA submission or whether we collect all the data and submit everything at the same time. So it's not impossible that the timeline will shrink, actually, and be less than six months, because we are ready for some of the modules, actually, to submit already. We've made tremendous progress. PRT-K05 was clearly on the critical path, so just to remind you, that's the clinical trial that we just discussed about biodistribution and shedding, and we have delivered on this. So we could submit, for example, the clinical and the non-clinical modules at an earlier time point, but this is a topic that we will discuss with the FDA.
Maury Raycroft, Analyst — Jefferies
Got it. And assuming complete submission in mid-27, do you continue to expect priority review and a potential approval first quarter of 28?
Paul Peter Tak, Board Member
Yeah, that's correct, because we have both fast-track designation and RMIT designation. We are in a relatively unique position, I would say, that we got and filed for the RMIT designation with the data in hand. There are not many examples of that. Many people have filed before that time, and then the data may be disappointing, and then everything is different. We went to the current FDA, and with the data in hand, we got RMIT designation. We already had a fast-track designation, which allows us to get priority review, we believe, and I think that's a great advantage.
Maury Raycroft, Analyst — Jefferies
Got it. Okay. And how firm is the current $250,000 to $300,000 pricing assumption, and what feedback have you received from payers on treating Agla Imogene as one-time therapy?
Paul Peter Tak, Board Member
Yeah, of course, we don't have a final price because it will need to be negotiated, but we've done quite a lot of market research and payer research, Especially lately, in close collaboration with our chief commercial officer, Mark Sims, and Eversana, which have been a great partner. And the price assumptions seem to be much better than we initially modeled, when we believed already that this is a blockbuster indication. This is a very big market, but it's basically no competition in this specific indication of intermediate to high-risk, localized prostate cancer patients who want to be treated with curative intent. So it is true that the range that we are looking at at this moment is in the order of 250 to 300,000 U.S. dollars for three administrations of Agla-Timington. And so what is it that the payers liked about this? First, the fact that we achieved the primary endpoint supported by multiple secondary and exploratory endpoints. That's one. The second point, there's no increase whatsoever in the number of serious adverse events. If you compare the aclactimidine arm versus placebo, so in the end, it's all about benefit-risk. And another thing to remind you, this is like a one-off treatment. Albeit consisting of three courses, but that's it. It's not a recurring cost to the health care system. And actually, it may help to reduce future costs to the health care system. Think of long-term ADT, etc. We've shown already with the data that we presented in the plenary oral session at the American Urology Association meeting that there's already an emerging trend when you compare aglatimidin versus placebo in terms of the time to salvage anti-cancer therapy. In most cases, that's long-term ADT. So all of these were seen as positives without pushback from the payers.
Maury Raycroft, Analyst — Jefferies
And some KOL feedback suggests that reducing or delaying hormone therapy could be one of the product's most meaningful benefits. Is there a path toward an ADT sparing claim, publication, or guideline recommendation, and would that require another study?
Paul Peter Tak, Board Member
Yeah, so it's interesting, right, because we get this consistent feedback. So our target healthcare professionals are urologists and radiation oncologists, right? They are the physicians who treat these patients, typically not the medical oncologists. And they've made it very clear, and we hear the same from patients and patient organizations, that a big unmet need in this space is the use of ADT, right? It works, right? Patients may live longer, but it has a negative impact on quality of life in at least two-thirds of the patients. So this is a huge medical unmet need. Many patients where it's indicated actually don't take it. Or they start taking it and stop it because of the side effects, because their life becomes quite miserable. So that's what we've heard from urologists and radiation oncologists. I should also say, the clinical trial... It was not designed formally to show that we can avoid or delay the need for ADT. We allowed, actually, the use of short-term ADT in our clinical trial. Based on normal clinical practice, we wanted to be as close as possible to a real-world clinical practice. Actually, the interesting thing is if you look at the most recent NCCN guidelines that came out October 12th, it's completely consistent with what we've done in our clinical trial, right, In intermediate-risk favorable disease, short-term ADT is not indicated. In intermediate-risk unfavorable disease, short-term ADT is basically the outcome of the shared decision-making between the physician and the patient. So we've not formally shown that, but again, I want to remind you where I went earlier. When you look at the AUA data, we're starting to show that we can delay or avoid the need for long-term salvage ADT. So I think this is how physicians will use it. And also, it's possible that after approval, we will initiate a new clinical trial in a different indication in prostate cancer. It's a huge opportunity for expansion of indications and to even increase the market even further. Think of oligometastatic disease. You could imagine that you design a trial that's formally designed to show that you can avoid or delay the need of ADT, which will also, I think, reinforce the use in localized prostate cancer if you formally show that you can actually avoid ADT in these patients.
Maury Raycroft, Analyst — Jefferies
Got it. And maybe talk about the, just, you extended the expected cash runway into the second quarter of 2028. What actions enabled that extension, and does the revised runway give you sufficient capital to complete the VLA submission?
Paul Peter Tak, Board Member
Yeah, absolutely. So we've used the ATM in a prudent way, and we've used it in Q2 and Q3 of this year at relatively high share prices, so we've minimized dilution. So this has helped us to extend the runway and give us a little bit more cushion. Also, we try to be extremely disciplined in terms of finance. I want to remind you of, for example, our commercial model. We have access to all the capabilities that we need. My background is in big pharma. I was on the commercial board, franchise board of GSK, among my role in R&D. So we've always known that we need to be ready for the regulators as much as possible, But also for the payers, the healthcare professionals, and the patients. But we did not want to build a big commercial infrastructure prematurely, because things may happen, like an asset that needs a little bit more time to show that it's fully validated. So we work in a model where we can switch things on and off, actually. And I'd like to build organizations top-down. So we brought in a very strong chief commercial officer to oversee this collaboration with Eversana, Idea Pharma, Globe Life Sciences, but it also helps us to not enter with a huge fixed cost, and we can delay some of the costs that we may not need at this time. And so I think this combination of financial discipline. And using the ATM in a very measured way has helped us to extend into Q2, getting to the BLA and into commercialization is in the current runway. So we are very happy about that. And I also want to remind you that if we get approval, we have a royalty deal with RTW, which will allow us to get access to another 100 million to really ramp up all the activities that we will need at that time for commercialization. I'm very keen on seeing very steep uptake in the commercial space. In fact, there's a silver lining of the delay that we have now due to the IU essay. Of course, that's not what I wanted, but then there is an upside to it, actually, because, A, we will have more time to educate the community. We do already a lot in educating people, and there's a lot of support from the scientific and medical communities, But it will be good to focus very much, especially on the 80% of the patients that are linked to just a few hundred accounts, so you can have a very focused effort there. Second, by having a little bit more time to get to the completion of the BLA submission, we will have a more extended shelf life, which is a commercial benefit as well. So clearly there are also upsides from a commercial perspective. And then there's a very interesting thing about the use of radiotherapy in a curative setting, and we hope that that will be combined with aglatimogen, which is there's a seasonal effect. Prostate cancer is typically a more slowly growing tumor than, let's say, pancreatic cancer or lung cancer. And we were aiming for launch in Q4, 2027. And we know that many patients who are diagnosed with low-class prostate cancer during that time will actually wait until after the holidays, Thanksgiving, Christmas, and will be treated in Q1. So now we aim for launch in Q1, 2028, and we believe, based on this seasonal effect that we've also seen in the clinical trial, actually, this is well established, that we will be set up for more successful commercialization.
Maury Raycroft, Analyst — Jefferies
Got it. All interesting, great points. We're out of time. Maybe in closing, if you want to highlight key events ahead that investors should be focused on.
Paul Peter Tak, Board Member
The key event remains, of course, the BLA submission. This is the absolute top priority for the company. We are doing enabling work for glioblastoma, for lean nozapatra. We should not forget that we have a second investigation on medicine that looks very, very exciting. And third, we will continue, of course, to work on non-sponsored lung cancer. We're rolling out the trial across the world, right? This is our first global clinical trial. We expect a publication based on pancreatic cancer in the very near future. We've not disclosed that, so I won't say which journal it is, but you can expect a publication in a few weeks. So all of that supports the validation of our science.
Maury Raycroft, Analyst — Jefferies
Got it. Paul Peter, thanks so much for joining us today.
Paul Peter Tak, Board Member
It was a great pleasure. Thank you so much. Thank you all.